Federated Hermes Inc. Cuts Stock Holdings in Medpace Holdings, Inc. $MEDP

Federated Hermes Inc. lowered its stake in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 62.4% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 12,003 shares of the company’s stock after selling 19,947 shares during the quarter. Federated Hermes Inc.’s holdings in Medpace were worth $6,171,000 at the end of the most recent quarter.

A number of other hedge funds have also recently bought and sold shares of MEDP. NewEdge Advisors LLC lifted its position in shares of Medpace by 22.1% during the first quarter. NewEdge Advisors LLC now owns 1,048 shares of the company’s stock valued at $319,000 after purchasing an additional 190 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its holdings in shares of Medpace by 3.8% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 81,817 shares of the company’s stock valued at $24,929,000 after acquiring an additional 3,010 shares in the last quarter. Geneos Wealth Management Inc. lifted its holdings in Medpace by 64.9% during the first quarter. Geneos Wealth Management Inc. now owns 94 shares of the company’s stock worth $29,000 after acquiring an additional 37 shares during the period. Sivia Capital Partners LLC purchased a new position in Medpace in the second quarter worth $296,000. Finally, Truist Financial Corp grew its stake in Medpace by 10.2% in the 2nd quarter. Truist Financial Corp now owns 12,898 shares of the company’s stock valued at $4,048,000 after purchasing an additional 1,197 shares during the period. 77.98% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Medpace

In related news, President Jesse J. Geiger sold 21,503 shares of Medpace stock in a transaction on Wednesday, November 5th. The stock was sold at an average price of $595.66, for a total transaction of $12,808,476.98. Following the completion of the sale, the president owned 15,000 shares of the company’s stock, valued at approximately $8,934,900. This trade represents a 58.91% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, VP Susan E. Burwig sold 20,000 shares of the business’s stock in a transaction dated Monday, November 24th. The stock was sold at an average price of $609.15, for a total value of $12,183,000.00. Following the transaction, the vice president owned 27,500 shares of the company’s stock, valued at approximately $16,751,625. The trade was a 42.11% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 341,695 shares of company stock valued at $205,718,239 in the last three months. Company insiders own 20.30% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts recently weighed in on the stock. Robert W. Baird set a $613.00 price target on shares of Medpace in a report on Friday, October 24th. Barclays lifted their price target on shares of Medpace from $485.00 to $525.00 and gave the stock an “underweight” rating in a report on Monday, December 15th. Weiss Ratings reissued a “buy (b)” rating on shares of Medpace in a research report on Wednesday, January 28th. BMO Capital Markets started coverage on Medpace in a research note on Thursday, November 13th. They set a “market perform” rating and a $600.00 price target for the company. Finally, Zacks Research downgraded shares of Medpace from a “strong-buy” rating to a “hold” rating in a report on Monday, January 12th. Two investment analysts have rated the stock with a Buy rating, ten have issued a Hold rating and three have given a Sell rating to the company’s stock. According to data from MarketBeat, Medpace currently has a consensus rating of “Reduce” and an average price target of $491.27.

Medpace Stock Up 1.0%

Shares of NASDAQ MEDP opened at $588.17 on Tuesday. The business has a 50-day simple moving average of $583.67 and a two-hundred day simple moving average of $534.27. Medpace Holdings, Inc. has a 52 week low of $250.05 and a 52 week high of $628.92. The company has a market cap of $16.57 billion, a P/E ratio of 41.13, a P/E/G ratio of 1.96 and a beta of 1.42.

Medpace Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.